These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 18094617)

  • 1. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo.
    Schwartz GG; Eads D; Naczki C; Northrup S; Chen T; Koumenis C
    Cancer Biol Ther; 2008 Mar; 7(3):430-6. PubMed ID: 18094617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells.
    Alagbala AA; Johnson CS; Trump DL; Posner GH; Foster BA
    Oncology; 2006; 70(6):483-92. PubMed ID: 17237623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells.
    Kumagai T; O'Kelly J; Said JW; Koeffler HP
    J Natl Cancer Inst; 2003 Jun; 95(12):896-905. PubMed ID: 12813173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppressive effect of 19-nor-1α-25-dihydroxyvitamin D2 on gastric cancer cells and peritoneal metastasis model.
    Park MR; Lee JH; Park MS; Hwang JE; Shim HJ; Cho SH; Chung IJ; Bae WK
    J Korean Med Sci; 2012 Sep; 27(9):1037-43. PubMed ID: 22969249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of 22-oxa-1,25-dihydroxyvitamin D3, maxacalcitol, on the proliferation of pancreatic cancer cell lines.
    Kawa S; Yoshizawa K; Nikaido T; Kiyosawa K
    J Steroid Biochem Mol Biol; 2005 Oct; 97(1-2):173-7. PubMed ID: 16039115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Action of low calcemic 1alpha,25-dihydroxyvitamin D3 analogue EB1089 in head and neck squamous cell carcinoma.
    Prudencio J; Akutsu N; Benlimame N; Wang T; Bastien Y; Lin R; Black MJ; Alaoui-Jamali MA; White JH
    J Natl Cancer Inst; 2001 May; 93(10):745-53. PubMed ID: 11353784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 19-Nor-1alpha,25-dihydroxyvitamin D2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations.
    Molnár I; Kute T; Willingham MC; Schwartz GG
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):539-43. PubMed ID: 15225834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 19-nor-1alpha,25-dihydroxyvitamin D(2) (paricalcitol): effects on clonal proliferation, differentiation, and apoptosis in human leukemic cell lines.
    Molnár I; Kute T; Willingham MC; Powell BL; Dodge WH; Schwartz GG
    J Cancer Res Clin Oncol; 2003 Jan; 129(1):35-42. PubMed ID: 12618899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3.
    Schwartz GG; Eads D; Rao A; Cramer SD; Willingham MC; Chen TC; Jamieson DP; Wang L; Burnstein KL; Holick MF; Koumenis C
    Carcinogenesis; 2004 Jun; 25(6):1015-26. PubMed ID: 14742320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D for the prevention and treatment of pancreatic cancer.
    Chiang KC; Chen TC
    World J Gastroenterol; 2009 Jul; 15(27):3349-54. PubMed ID: 19610135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paricalcitol, a vitamin d receptor activator, inhibits tumor formation in a murine model of uterine fibroids.
    Halder SK; Sharan C; Al-Hendy O; Al-Hendy A
    Reprod Sci; 2014 Sep; 21(9):1108-19. PubMed ID: 24925855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
    Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
    Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol prevents cisplatin-induced renal injury by suppressing apoptosis and proliferation.
    Park JW; Cho JW; Joo SY; Kim CS; Choi JS; Bae EH; Ma SK; Kim SH; Lee J; Kim SW
    Eur J Pharmacol; 2012 May; 683(1-3):301-9. PubMed ID: 22449373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the vitamin D analogues paricalcitol and calcitriol on bone mineral in vitro.
    Balint E; Marshall CF; Sprague SM
    Am J Kidney Dis; 2000 Oct; 36(4):789-96. PubMed ID: 11007682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice.
    Becker LE; Koleganova N; Piecha G; Noronha IL; Zeier M; Geldyyev A; Kökeny G; Ritz E; Gross ML
    Am J Physiol Renal Physiol; 2011 Mar; 300(3):F772-82. PubMed ID: 21159735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effect of 220-oxa-1,25-dihydroxyvitamin D3 on the proliferation of pancreatic cancer cell lines.
    Kawa S; Yoshizawa K; Tokoo M; Imai H; Oguchi H; Kiyosawa K; Homma T; Nikaido T; Furihata K
    Gastroenterology; 1996 May; 110(5):1605-13. PubMed ID: 8613068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.
    Capuano A; Serio V; Pota A; Memoli B; Andreucci VE
    J Nephrol; 2009; 22(1):59-68. PubMed ID: 19229819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effects of vitamin D analogs on vascular calcification.
    Cardús A; Panizo S; Parisi E; Fernandez E; Valdivielso JM
    J Bone Miner Res; 2007 Jun; 22(6):860-6. PubMed ID: 17352647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of 1alpha,24(S)-dihydroxyvitamin D(2) analog on cancer cell proliferation and cytokine expression.
    Shany S; Levy Y; Lahav-Cohen M
    Steroids; 2001; 66(3-5):319-25. PubMed ID: 11179740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of 1α,25-dihydroxyvitamin D3 involves upregulation of cyclin-dependent kinase inhibitor p21 in human pancreatic cancer cells.
    Kanemaru M; Maehara N; Chijiiwa K
    Hepatogastroenterology; 2013; 60(125):1199-205. PubMed ID: 23803383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.